Familial Cancer最新文献

筛选
英文 中文
High amount of fertility reducing tumors and procedures, but no evidence for premature ovarian failure in female Lynch syndrome patients. 大量减少生育能力的肿瘤和手术,但没有证据表明女性林奇综合征患者会出现卵巢早衰。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-11-01 Epub Date: 2024-01-27 DOI: 10.1007/s10689-024-00357-4
Sabine Biermann, Michael Knapp, Peter Wieacker, Stefan Aretz, Verena Steinke-Lange
{"title":"High amount of fertility reducing tumors and procedures, but no evidence for premature ovarian failure in female Lynch syndrome patients.","authors":"Sabine Biermann, Michael Knapp, Peter Wieacker, Stefan Aretz, Verena Steinke-Lange","doi":"10.1007/s10689-024-00357-4","DOIUrl":"10.1007/s10689-024-00357-4","url":null,"abstract":"<p><p>Lynch syndrome (LS; HNPCC) patients carry heterozygous pathogenic germline variants in mismatch repair (MMR) genes, which have also been shown to play an important role in meiosis. Therefore, it was hypothesized, that LS might be associated with a higher risk for premature ovarian failure (POF) or earlier menopause. Data on medical gynaecological history, cancer diagnoses and therapy were collected from 167 female LS patients and compared to a population-based control cohort. There was no difference between the age of menopause in patients compared to controls and no evidence for a higher risk of POF in LS patients. However, around one third (35%) of the probands have already had premenopausal cancer and mostly cancer-related treatment affecting fertility before the age of 45 years. Therefore, childbearing time might still be limited in these patients, especially due to the premenopausal cancer risk. LS patients should be informed in time about the elevated premenopausal cancer risks and the possible impact on family planning. This is particularly relevant since the average childbearing age has increased during the last decades.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"473-478"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic screening for identification of signet ring cell gastric cancer foci in carriers of germline pathogenic variants in CDH1 通过内镜筛查识别 CDH1 基因致病变异携带者的标志环细胞胃癌病灶
IF 2.2 4区 医学
Familial Cancer Pub Date : 2024-09-11 DOI: 10.1007/s10689-024-00421-z
Lady Katherine Mejia Perez, Margaret O’Malley, Arjun Chatterjee, Ruishen Lyu, Qijun Yang, Michael W. Cruise, Lisa LaGuardia, David Liska, Carole Macaron, R. Matthew Walsh, Carol A. Burke
{"title":"Endoscopic screening for identification of signet ring cell gastric cancer foci in carriers of germline pathogenic variants in CDH1","authors":"Lady Katherine Mejia Perez, Margaret O’Malley, Arjun Chatterjee, Ruishen Lyu, Qijun Yang, Michael W. Cruise, Lisa LaGuardia, David Liska, Carole Macaron, R. Matthew Walsh, Carol A. Burke","doi":"10.1007/s10689-024-00421-z","DOIUrl":"https://doi.org/10.1007/s10689-024-00421-z","url":null,"abstract":"<p>To determine the preoperative detection of signet ring cancer cells (SRC) on upper endoscopy (EGD) in patients with <i>CDH1</i> pathogenic variant (PV) undergoing gastrectomy. To evaluate the development of advanced diffuse gastric cancer (DGC) in patients choosing surveillance. Guidelines recommend prophylactic total gastrectomy (pTG) in <i>CDH1</i> PV carriers with family history of DGC between 18 and 40 years. Annual EGD with biopsies according to established protocols is recommended in carriers with no SRC and no family history of DGC, with consideration of pTG. Retrospective analysis of asymptomatic patients with <i>CDH1</i> PVs with ≥ 1 surveillance EGD. Outcomes included pre-operative EGD detection of SRC, surgical stage, and progression to advanced DGC in those electing surveillance with EGD. 48 patients with <i>CDH1</i> PVs who had ≥ 1 EGD were included. 24/ 48 (50%) underwent gastrectomy, including pTG in 7 patients. SRCC were detected on gastrectomy specimen in 21/24 (87.5%). SRCs were identified by EGD in 17/21 patients who had SRCC on gastrectomy specimens (sensitivity 81%, 17/21). All cancers were stage pT1a. The remaining 17 patients (50% with a family history of gastric cancer) continue in annual EGD surveillance with a median follow-up of 34.6 months. No SRCC or advanced DGC have been diagnosed. No <i>CDH1</i> PV carriers without SRCC on random biopsies followed in an endoscopic program developed advanced DGC over a median follow up of 3 years. In the short term, EGD surveillance might be a safe alternative to immediate pTG in experienced hands in referral centers.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":"87 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142176694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review. 一名生殖系 BRCA2 变异携带者的胰腺尖细胞癌对铂和奥拉帕尼治疗的反应:病例报告和文献综述。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-05-11 DOI: 10.1007/s10689-024-00390-3
Hiroyuki Matsubayashi, Akiko Todaka, Takahiro Tsushima, Yoshimi Kiyozumi, Rina Harada, Eiko Ishihara, Satomi Higashigawa, Nobuyuki Ohike, Hiroki Sakamoto, Junya Sato, Hirotoshi Ishiwatari, Teichi Sugiura, Katsuhiko Uesaka
{"title":"The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review.","authors":"Hiroyuki Matsubayashi, Akiko Todaka, Takahiro Tsushima, Yoshimi Kiyozumi, Rina Harada, Eiko Ishihara, Satomi Higashigawa, Nobuyuki Ohike, Hiroki Sakamoto, Junya Sato, Hirotoshi Ishiwatari, Teichi Sugiura, Katsuhiko Uesaka","doi":"10.1007/s10689-024-00390-3","DOIUrl":"10.1007/s10689-024-00390-3","url":null,"abstract":"<p><p>A 73-year-old Japanese man with a history of distal biliary cancer treated by pancreatoduodenectomy developed pancreatic acinar cell carcinoma (PACC) treated by remnant pancreatectomy and adjuvant chemotherapy. Thirteen months after surgery, multiple liver metastases developed and FOLFOX chemotherapy was initiated. Based on the PACC diagnosis and a positive family history for breast and ovarian cancer genetic testing was performed which revealed a pathogenic germline BRCA2 variant (c.8629G > T, p.Glu2877Ter). Olaparib therapy was initiated and the metastases responded well (partial response). PACC is a BRCA2-associated cancer which may respond well to PARP inhibitors.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"393-398"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue. 家族性和遗传性胰腺导管腺癌监测二十五年:历史展望和特刊导言。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-06-06 DOI: 10.1007/s10689-024-00404-0
Hans Fa Vasen, Marcia Irene Canto, Michael Goggins
{"title":"Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue.","authors":"Hans Fa Vasen, Marcia Irene Canto, Michael Goggins","doi":"10.1007/s10689-024-00404-0","DOIUrl":"10.1007/s10689-024-00404-0","url":null,"abstract":"<p><p>In the 1990s, as prevention became a central strategy in the battle against cancer and the molecular genetics revolution uncovered the genetic basis of numerous hereditary cancer syndromes, there were no options available for patients at increased risk of developing pancreatic cancer. When surveillance efforts for those at familial and hereditary risk of pancreatic cancer emerged in the late 1990s, it was uncertain if early detection was achievable.In this introduction to the special issue, we offer an overview of the history of surveillance for pancreatic cancer, including the first reports of familial pancreatic cancer in the medical literature, the initial results of surveillance in the United States and the initiation of surveillance programs for hereditary pancreatic cancer in the Netherlands.This special issue features a collection of 18 articles written by prominent experts in the field, focusing specifically on refining surveillance methodologies with the primary objective of improving care of high-risk individuals. Several reviews in this collection highlight improved survival rates associated with pancreas surveillance, underlying the potential of early detection and improved management in the continuing fight against pancreatic cancer.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"209-215"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial and hereditary pancreatic cancer in Japan. 日本的家族性和遗传性胰腺癌。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-05-11 DOI: 10.1007/s10689-024-00395-y
Hiroyuki Matsubayashi, Chigusa Morizane
{"title":"Familial and hereditary pancreatic cancer in Japan.","authors":"Hiroyuki Matsubayashi, Chigusa Morizane","doi":"10.1007/s10689-024-00395-y","DOIUrl":"10.1007/s10689-024-00395-y","url":null,"abstract":"<p><p>As in Western countries, familial pancreatic cancer accounts for 5-7% of pancreatic cancer (PC) in Japan. Opportunities for diagnosing hereditary pancreatic cancer (HPC) are increasing owing to the coverage of companion diagnostics and cancer genomic profiling by national health insurance in patients with unresectable or recurrent PC refractory to standard chemotherapies. HPC is recognized in 7% of PCs and 15% of familial pancreatic cancer, including germline variants of BRCA1/2, ATM, PALB2, APC, and mismatch repair genes. Individuals with 5-fold or greater inherited risks of PC are recommended to undergo pancreatic surveillance according to Japanese guidelines. The imaging modalities for this surveillance include endoscopic ultrasound, magnetic resonance cholangiopancreatography, abdominal ultrasound, and enhanced computed tomography. Currently, a nationwide prospective surveillance study is ongoing in Japan. Platinum-based chemotherapy is an effective pancreatic cancer treatment in patients with variants of homologous recombination repair genes (BRCA1/2 and PALB2); however, the use of platinum regimens solely based on familial/personal cancer history remains controversial. The efficacy of olaparib maintenance therapy, as confirmed by the POLO study, has significantly impacted the clinical treatment of advanced PC patients in Japan. Since the initiation of precision cancer medicine in 2019, genetic medicine for PC patients has expanded in Japan.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"365-372"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant. 种系 CDKN2A 致病变异家庭对基因检测、计划生育和植入前基因检测的态度。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-06-01 DOI: 10.1007/s10689-024-00401-3
A M Onnekink, D C F Klatte, J E van Hooft, S H van den Berg, S M S van der Zwaan, R van Doorn, S C H Hinnen, T P Potjer, E M A Bleiker, M E van Leerdam
{"title":"Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant.","authors":"A M Onnekink, D C F Klatte, J E van Hooft, S H van den Berg, S M S van der Zwaan, R van Doorn, S C H Hinnen, T P Potjer, E M A Bleiker, M E van Leerdam","doi":"10.1007/s10689-024-00401-3","DOIUrl":"10.1007/s10689-024-00401-3","url":null,"abstract":"<p><p>Individuals with a germline CDKN2A pathogenic variant (PV) have a highly increased life time risk of melanoma and pancreatic cancer. This cross-sectional study assessed the attitudes among toward genetic testing, family planning, and preimplantation genetic testing (PGT) in confirmed CDKN2A PV carriers and individuals with a 50% risk of the PV (at-risk carriers) using of a one-time questionnaire.A total of 537 individuals were screened for eligibility, of whom 208 of 366 (57%) confirmed carriers (56% female, median age 54 years [IQR 46-63]) and 39 of 171 (23%) at-risk carriers (59% female, median age of 26 years [IQR 22-32]) participated in the study. Primary motivations for genetic testing were to gain control over their personal and children's cancer risk, as well as increasing cancer surveillance practices. In contrast, concerns about obtaining a mortgage and life insurance were frequently cited as reasons for postponing genetic testing. Family planning decisions remained largely unaffected in both confirmed and at-risk carriers; however, the majority of confirmed carriers were still unaware of their familial or personal cancer risk when starting a family. More than 60% of the participants were unfamiliar with PGT and only a minority (19% of confirmed carriers and 10% of at-risk carriers) would be open to considering PGT as a reproductive option. This study found different attitudes toward genetic testing, family planning, and PGT among individuals affected by the CDKN2A PV. Understanding these different attitudes can help clinicians to address the complexities surrounding these issues, especially for younger individuals facing difficult decisions about the timing of genetic testing, family planning, and the potential use of assisted reproductive options.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"255-265"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. 利用磁共振成像筛查高危人群中的胰腺癌:优化扫描技术以检测微小病灶。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-05-11 DOI: 10.1007/s10689-024-00394-z
Bas Boekestijn, Shirin Feshtali, Hans Vasen, Monique E van Leerdam, Bert A Bonsing, J Sven D Mieog, Martin N Wasser
{"title":"Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions.","authors":"Bas Boekestijn, Shirin Feshtali, Hans Vasen, Monique E van Leerdam, Bert A Bonsing, J Sven D Mieog, Martin N Wasser","doi":"10.1007/s10689-024-00394-z","DOIUrl":"10.1007/s10689-024-00394-z","url":null,"abstract":"<p><p>Pancreatic cancer has a dismal prognosis in the general population. However, early detection and treatment of disease in high-risk individuals can improve survival, as patients with localized disease and especially patients with lesions smaller than 10 mm show greatly improved 5-year survival rates. To achieve early detection through MRI surveillance programs, optimization of imaging is required. Advances in MRI technologies in both hardware and software over the years have enabled reliable detection of pancreatic cancer at a small size and early stage. Standardization of dedicated imaging protocols for the pancreas are still lacking. In this review we discuss state of the art scan techniques, sequences, reduction of artifacts and imaging strategies that enable early detection of lesions. Furthermore, we present the imaging features of small pancreatic cancers from a large cohort of high-risk individuals. Refinement of MRI techniques, increased scan quality and the use of artificial intelligence may further improve early detection and the prognosis of pancreatic cancer in a screening setting.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"295-308"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. 遗传性胰腺癌监测成本效益回顾。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-05-25 DOI: 10.1007/s10689-024-00392-1
Louise Wang, Rachel Levinson, Catherine Mezzacappa, Bryson W Katona
{"title":"Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer.","authors":"Louise Wang, Rachel Levinson, Catherine Mezzacappa, Bryson W Katona","doi":"10.1007/s10689-024-00392-1","DOIUrl":"10.1007/s10689-024-00392-1","url":null,"abstract":"<p><p>Individuals with hereditary pancreatic cancer risk include high risk individuals (HRIs) with germline genetic susceptibility to pancreatic cancer (PC) and/or a strong family history of PC. Previously, studies have shown that PC surveillance in HRIs can downstage PC diagnosis and extend survival leading to pancreatic surveillance being recommended for certain HRIs. However, the optimal surveillance strategy remains uncertain, including which modalities should be used for surveillance, how frequently should surveillance be performed, and which sub-groups of HRIs should undergo surveillance. Additionally, in the ideal world PC surveillance should also be cost-effective. Cost-effectiveness analysis is a valuable tool that can consider the costs, potential health benefits, and risks among various PC surveillance strategies. In this review, we summarize the cost-effectiveness of various PC surveillance strategies for HRIs for hereditary pancreatic cancer and provide potential avenues for future work in this field. Additionally, we include cost-effectiveness studies among individuals with new-onset diabetes (NoD), a high-risk group for sporadic PC, as a comparison.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"351-360"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141096845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precursor lesions in familial and hereditary pancreatic cancer. 家族性和遗传性胰腺癌的前驱病变。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-02-06 DOI: 10.1007/s10689-024-00359-2
Michael J Pflüger, Lodewijk A A Brosens, Ralph H Hruban
{"title":"Precursor lesions in familial and hereditary pancreatic cancer.","authors":"Michael J Pflüger, Lodewijk A A Brosens, Ralph H Hruban","doi":"10.1007/s10689-024-00359-2","DOIUrl":"10.1007/s10689-024-00359-2","url":null,"abstract":"<p><p>Infiltrating ductal adenocarcinoma of the pancreas, referred to here as \"pancreatic cancer,\" is one of the deadliest of all of the solid malignancies. The five-year survival rate in the United States for individuals diagnosed today with pancreatic cancer is a dismal 12%. Many invasive cancers, including pancreatic cancer, however, arise from histologically and genetically well-characterized precursor lesions, and these precancers are curable. Precursor lesions therefore are an attractive target for early detection and treatment. This is particularly true for individuals with an increased risk of developing invasive cancer, such as individuals with a strong family history of pancreatic cancer, and individuals with a germline variant known to increase the risk of developing pancreatic cancer. There is therefore a need to understand the precursor lesions that can give rise to invasive pancreatic cancer in these individuals.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"267-278"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants. 将最佳线性无偏预测法(BLUP)作为一种工具,用于估算没有已知致病基因变异的高危人群终生胰腺导管腺癌的风险。
IF 1.8 4区 医学
Familial Cancer Pub Date : 2024-08-01 Epub Date: 2024-05-23 DOI: 10.1007/s10689-024-00397-w
Cristina-Marianini-Rios, María E Castillo Sanchez, Ana García García de Paredes, Mercedes Rodríguez, Emma Barreto, Jorge Villalón López, Raquel Fuentes, María Muñoz Beltrán, Alfonso Sanjuanbenito, Eduardo Lobo, Alejandra Caminoa, Ignacio Ruz-Caracuel, Sergio López Durán, José Ramón Foruny Olcina, Javier Blázquez, Enrique Vázquez Sequeros, Alfredo Carrato, Jose Carlos Martínez Ávila, Julie Earl
{"title":"The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants.","authors":"Cristina-Marianini-Rios, María E Castillo Sanchez, Ana García García de Paredes, Mercedes Rodríguez, Emma Barreto, Jorge Villalón López, Raquel Fuentes, María Muñoz Beltrán, Alfonso Sanjuanbenito, Eduardo Lobo, Alejandra Caminoa, Ignacio Ruz-Caracuel, Sergio López Durán, José Ramón Foruny Olcina, Javier Blázquez, Enrique Vázquez Sequeros, Alfredo Carrato, Jose Carlos Martínez Ávila, Julie Earl","doi":"10.1007/s10689-024-00397-w","DOIUrl":"10.1007/s10689-024-00397-w","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the Western world. The number of diagnosed cases and the mortality rate are almost equal as the majority of patients present with advanced disease at diagnosis. Between 4 and 10% of pancreatic cancer cases have an apparent hereditary background, known as hereditary pancreatic cancer (HPC) and familial pancreatic cancer (FPC), when the genetic basis is unknown. Surveillance of high-risk individuals (HRI) from these families by imaging aims to detect PDAC at an early stage to improve prognosis. However, the genetic basis is unknown in the majority of HRIs, with only around 10-13% of families carrying known pathogenic germline mutations. The aim of this study was to assess an individual's genetic cancer risk based on sex and personal and family history of cancer. The Best Linear Unbiased Prediction (BLUP) methodology was used to estimate an individual's predicted risk of developing cancer during their lifetime. The model uses different demographic factors in order to estimate heritability. A reliable estimation of heritability for pancreatic cancer of 0.27 on the liability scale, and 0.07 at the observed data scale as obtained, which is different from zero, indicating a polygenic inheritance pattern of PDAC. BLUP was able to correctly discriminate PDAC cases from healthy individuals and those with other cancer types. Thus, providing an additional tool to assess PDAC risk HRI with an assumed genetic predisposition in the absence of known pathogenic germline mutations.</p>","PeriodicalId":12336,"journal":{"name":"Familial Cancer","volume":" ","pages":"233-246"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141081164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信